Myeloablative allogeneic stem cell transplant for AML and MDS: the impact of advanced age in the outcome

被引：0
|
作者：
Sanchez-Escamilla, M. [1 ,2 ]
Garcia-Avila, S. [1 ]
Yanez San Segundo, L. [1 ,2 ]
Bermudez Rodriguez, M. A. [1 ,2 ]
Colorado Araujo, M. M. [1 ,2 ]
Casado Diez, A. [1 ]
Celis Alvarez, M. [1 ]
Cabero Martinez, A. [1 ]
Fernandez Martinez, C. [1 ]
Insunza Garminde, A. [1 ,2 ]
Richard Espiga, C. [1 ,2 ]
Conde Garcia, E. [1 ,2 ]
机构：
[1] Marques de Valdecilla Univ Hosp, Santander, Spain
[2] IDIVAL, Santander, Spain
来源：
BONE MARROW TRANSPLANTATION | 2017年 / 52卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P415
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [1] Non-myeloablative stem cell transplant (NMSCT) in AML, ALL, and MDS: Disappointing outcome for patients with advanced phase disease.
    Rezvani, K
    Lalancette, M
    Szydlo, R
    Mackinnon, S
    Blaise, D
    Slavin, S
    Alessandrino, EP
    Michallet, M
    Niederwieser, N
    Apperley, J
    Frassoni, F
    BLOOD, 2000, 96 (11) : 479A - 479A
  • [2] Microbiota analysis in allogeneic stem cell transplant patients with in AML and MDS
    Gurer, Ekin Ece
    Oguz, Fatma Savran
    Aktas, Zerrin
    Kalayoglu, Sevgi Besisik
    Oncul, Mustafa Oral
    Sezerman, Osman Ugur
    Ekren, Berkay
    Caliskan, Kader
    Gulbas, Zafer
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 326 - 326
  • [3] Impact of comorbidity on the outcome of allogeneic hematopoietic stem cell transplantation in AML/MDS patients.
    Shahjahan, M
    Alamo, J
    Delima, M
    Khouri, I
    Gajewski, J
    Andersson, BS
    Champlin, RE
    Giralt, S
    BLOOD, 2003, 102 (11) : 708A - 708A
  • [4] T cell depleted (TCD) allogeneic hematopoietic stem cell transplant for older patients with advanced MDS and AML evolved from MDS
    Tamari, R.
    Chung, S.
    Devlin, S.
    Jakubowski, A.
    Papadopoulos, E.
    Perales, M. A.
    Ponce, D.
    Goldberg, J.
    Barker, J.
    Sauter, C.
    Koehne, G.
    Young, J.
    Giralt, S.
    Castro-Malaspina, H.
    LEUKEMIA RESEARCH, 2013, 37 : S122 - S122
  • [5] A Retrospective Comparison of Outcomes in AML/MDS Patients Undergoing Allogeneic Stem Cell Transplant with Reduced Intensity and Myeloablative Conditioning Regimens
    Albabtain, Abdulwahab
    Kim, Seongho
    Uberti, Joseph
    Ratanatharathorn, Voravit
    Deol, Abhinav
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S258 - S259
  • [6] PROGNOSTIC IMPACT OF MIXED CHIMERISM AND MINIMAL RESIDUAL DISEASE IN MDS/AML AFTER ALLOGENEIC STEM CELL TRANSPLANT
    Bernal, T.
    Diez Campelo, M.
    Godoy, V.
    Alcoceba, M.
    Rojas, S.
    GonzaLez Diaz, M.
    Colado, E.
    Luno, E.
    Sanchez-Guijo, F.
    Lopez Corral, L.
    Del Canizo, M.
    HAEMATOLOGICA, 2012, 97 : 409 - 409
  • [7] Non-Myeloablative Stem Cell Transplantation (NMSCT) in AML, ALL and MDS: disappointing outcome for patients with advanced phase disease
    Rezvani, K
    Lalancette, M
    Szydlo, R
    Blaise, D
    Slavin, S
    Alessandrino, P
    Michallet, M
    Niederwieser, D
    Apperley, J
    Frassoni, F
    BONE MARROW TRANSPLANTATION, 2001, 27 : S279 - S279
  • [8] The Management of Relapsed AML or MDS Following a T-Cell Depleted Allogeneic Stem Cell Transplant
    Morawa, Ewelina
    Zabor, Emily
    Maloy, Molly
    Devlin, Sean
    Giralt, Sergio A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2013, 19 (02) : S300 - S300
  • [9] Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation
    Heuser, Michael
    Koenecke, Christian
    Gabdoulline, Razif
    Loeffeld, Patrick
    Dobbernack, Vera
    Panagiota, Victoria
    Klesse, Sabrina
    Stadler, Michael
    Krauter, Juergen
    Dammann, Elke
    Wichmann, Martin
    Shahswar, Rabia
    Bhuju, Sabin
    Geffers, Robert
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Kleine, Moritz
    Brauns, Wiebke
    Platzbecker, Uwe
    Thiede, Christian
    Schroeder, Thomas
    Kobbe, Guido
    Ganser, Arnold
    Kroeger, Nicolaus
    Thol, Felicitas
    BLOOD, 2015, 126 (23)
  • [10] Allogeneic myeloablative stem cell transplant as salvage therapy of reduced-intensity conditioned stem cell transplant: toxicity and outcome
    Cordonnier, C
    Hamladji, R
    Gratwohl, A
    Ljungman, P
    Martino, R
    Bordigoni, P
    Francois, S
    Deconninck, E
    Buzyn, A
    Bay, J
    Fouillard, L
    Kuentz, M
    BONE MARROW TRANSPLANTATION, 2006, 37 : S195 - S195
12345